About Invivyd, Inc.
https://adagiotx.comAdagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
CEO
William E. Duke Jr.,
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 25
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:25.38M
Value:$66M
POINT72 ASSET MANAGEMENT, L.P.
Shares:20.3M
Value:$52.79M
MAVERICK CAPITAL LTD
Shares:18.97M
Value:$49.32M
Summary
Showing Top 3 of 84
About Invivyd, Inc.
https://adagiotx.comAdagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $13.13M ▲ | $23.06M ▼ | $-10.47M ▲ | -79.75% ▲ | $-0.06 ▲ | $-10.04M ▲ |
| Q2-2025 | $11.79M ▲ | $26.16M ▼ | $-14.66M ▲ | -124.38% ▲ | $-0.12 ▲ | $-14.56M ▲ |
| Q1-2025 | $11.3M ▼ | $27.39M ▼ | $-16.29M ▲ | -144.1% ▼ | $-0.14 ▲ | $-16.18M ▲ |
| Q4-2024 | $13.82M ▲ | $32.33M ▼ | $-18.44M ▲ | -133.45% ▲ | $-0.15 ▲ | $-17.71M ▲ |
| Q3-2024 | $9.3M | $70.81M | $-60.74M | -653.11% | $-0.51 | $-61.75M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $84.97M ▲ | $139.16M ▲ | $46.09M ▼ | $93.07M ▲ |
| Q2-2025 | $34.91M ▼ | $89.14M ▼ | $46.35M ▼ | $42.79M ▼ |
| Q1-2025 | $48.08M ▼ | $103.74M ▼ | $49.59M ▼ | $54.15M ▼ |
| Q4-2024 | $69.35M ▼ | $129.51M ▼ | $61.98M ▼ | $67.54M ▼ |
| Q3-2024 | $106.87M | $161.92M | $78.76M | $83.16M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-10.47M ▲ | $-8.25M ▲ | $0 ▲ | $58.31M ▲ | $50.06M ▲ | $-8.25M ▲ |
| Q2-2025 | $-14.66M ▲ | $-13.3M ▲ | $-11K ▲ | $131K ▲ | $-13.17M ▲ | $-13.31M ▲ |
| Q1-2025 | $-16.29M ▲ | $-21.13M ▲ | $-144K ▼ | $10K ▼ | $-21.27M ▲ | $-21.27M ▲ |
| Q4-2024 | $-18.44M ▲ | $-37.61M ▲ | $5K ▲ | $77K ▲ | $-37.52M ▲ | $-37.6M ▲ |
| Q3-2024 | $-60.74M | $-41.07M | $-5K | $61K | $-41.01M | $-41.07M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
CEO
William E. Duke Jr.,
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 25
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:25.38M
Value:$66M
POINT72 ASSET MANAGEMENT, L.P.
Shares:20.3M
Value:$52.79M
MAVERICK CAPITAL LTD
Shares:18.97M
Value:$49.32M
Summary
Showing Top 3 of 84